<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01196845</url>
  </required_header>
  <id_info>
    <org_study_id>09-CHUG-25</org_study_id>
    <secondary_id>2009-A00826-51</secondary_id>
    <nct_id>NCT01196845</nct_id>
  </id_info>
  <brief_title>Inflammation and Oxidative Stress of Adipose Tissue in Sleep Apnea Syndrome</brief_title>
  <acronym>ADISAS</acronym>
  <official_title>Inflammation and Oxidative Stress of Adipose Tissue in Obese and Non-obese Patients Having Sleep Apnea Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to evaluate the decrease of inflammation of adipose
      tissue in obese and non-obese patients having a sleep apnea syndrome and treated or not by
      continuous positive airway pressure (cPAP).

      An interim analysis will be performed when 40 patients will be included.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inflammation of adipose tissue will be evaluated by RT-PCR on mRNA of pro and
      anti-inflammatory cytokines (IL-1, IL-6, IL-4, IL-10, IL-12, RANTES, TNFa, leptin,
      adiponectin, CD68).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease of inflammation in adipose tissue</measure>
    <time_frame>2 months</time_frame>
    <description>Obese and non-obese patients having a sleep apnea syndrome will be treated by cPAP or not (placebo arm). Decrease of inflammation in adipose tissue is expected to be observed in patients treated by cPAP.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decrease of oxidative stress</measure>
    <time_frame>2 months</time_frame>
    <description>Measures of oxidative stress will be done in obese and non-obese patients treated either by cPAP or &quot;Placebo cPAP&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of insulin sensitivity</measure>
    <time_frame>2 months</time_frame>
    <description>Insulin sensitivity will be measured in obese and non-obese patients treated either by cPAP or &quot;placebo cPAP&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease of systemic inflammation</measure>
    <time_frame>2 months</time_frame>
    <description>This measure will be done in obese and non-obese patients treated either by cPAP or &quot;placebo cPAP&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of local hypoxemia of adipose tissue</measure>
    <time_frame>2 months</time_frame>
    <description>This measure will be done in obese and non-obese patients treated either by cPAP or &quot;placebo cPAP&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of structural and functional changes in skeletal muscle</measure>
    <time_frame>2 months</time_frame>
    <description>This measure will be done in obese and non-obese patients treated either by cPAP or &quot;placebo cPAP&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of vascular adhesion factors modifications and protein synthesis signals modifications</measure>
    <time_frame>2 months</time_frame>
    <description>This measure will be done in musculus skeletal of obese and non-obese patients treated either by cPAP or &quot;placebo cPAP&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in endothelial dysfunction</measure>
    <time_frame>2 months</time_frame>
    <description>This measure will be done in obese and non-obese patients treated either by cPAP or &quot;placebo cPAP&quot; and correlated to decrease of inflammation and oxidative stress</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in arterial rigidity</measure>
    <time_frame>2 months</time_frame>
    <description>This measure will be done in obese and non-obese patients treated either by cPAP or &quot;placebo cPAP&quot; and correlated to decrease of inflammation and oxidative stress</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Decrease of Inflammation of Adipose Tissue</condition>
  <condition>Sleep Apnea Syndrome</condition>
  <arm_group>
    <arm_group_label>obese + cPAP</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with sleep apnea syndrome will be first randomised in 2 arms according to their obesity. They will be secondly randomised in 2 arms receiving either cPAP treatment or Sham cPAP.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>obese + Sham cPAP</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with sleep apnea syndrome will be first randomised in 2 arms according to their obesity. They will be secondly randomised in 2 arms receiving either cPAP treatment or Sham cPAP.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-obese + cPAP</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with sleep apnea syndrome will be first randomised in 2 arms according to their obesity. They will be secondly randomised in 2 arms receiving either cPAP treatment or Sham cPAP.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-obese + Sham cPAP</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with sleep apnea syndrome will be first randomised in 2 arms according to their obesity. They will be secondly randomised in 2 arms receiving either cPAP treatment or Sham cPAP.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>cPAP</intervention_name>
    <description>Patients are randomised in 2 arms : cPAP or sham cPAP</description>
    <arm_group_label>obese + cPAP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>cPAP</intervention_name>
    <description>Patients are randomised in 2 arms : cPAP or Sham cPAP</description>
    <arm_group_label>obese + Sham cPAP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>cPAP</intervention_name>
    <description>Patients are randomised in 2 arms : cPAP or sham cPAP</description>
    <arm_group_label>non-obese + cPAP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>cPAP</intervention_name>
    <description>Patients are randomised in 2 arms : cPAP or sham cPAP</description>
    <arm_group_label>non-obese + Sham cPAP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male between 18 and 70 years old

          -  Apnea Hypopnea Index &gt; 30/h and &gt; 5% TST with SaO2 &lt; 90%

          -  patients obese (BMI &gt; 33kg/m2) or non obese (BMI &lt; 27kg/m2)

        Exclusion Criteria:

          -  Female

          -  coronary ischemic disease, past history of CVA

          -  chronic pulmonary disease measured by arterial gasometry (PaO2 &lt; 60mmHg and/or PaCO2 &gt;
             45mmHg)

          -  known hepatic disease

          -  alcohol consumption &gt; 3 units/day

          -  sleepiness considered to be dangerous by the investigator

          -  patient having an hazardous work regarding to awareness

          -  patient being under anticoagulant, antiplatelet drug or having an active stent or
             bleeding disorder

          -  patient having an inflammatory syndrome (C-reactive Protein &gt; 10)

          -  any allergy to local anaesthetics

          -  chronic muscle pain

          -  contraindication to MRI
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Louis PEPIN, ProfessorPhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean Louis PEPIN, ProfessorPhD</last_name>
    <phone>0033476765516</phone>
    <phone_ext>65516</phone_ext>
    <email>JPepin@chu-grenoble.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Louis PEPIN, ProfessorPhD</last_name>
      <phone>0033476765516</phone>
      <email>JPepin@chu-grenoble.fr</email>
    </contact>
    <contact_backup>
      <last_name>Renaud TAMISIER</last_name>
      <phone>0033476768469</phone>
      <email>RTamisier@chu-grenoble.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Patrick LEVY, ProfessorPhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Renaud TAMISIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandrine LAUNOIS ROLLINAT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean Philippe BAGUET, ProfessorPhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Serge HALIMI, ProfessorPhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrice FAURE, ProfessorPhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Denis MONNERET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernard WUYAM, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne Laure BOREL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Baguet JP, Hammer L, Lévy P, Pierre H, Launois S, Mallion JM, Pépin JL. The severity of oxygen desaturation is predictive of carotid wall thickening and plaque occurrence. Chest. 2005 Nov;128(5):3407-12.</citation>
    <PMID>16304292</PMID>
  </reference>
  <reference>
    <citation>Shamsuzzaman AS, Gersh BJ, Somers VK. Obstructive sleep apnea: implications for cardiac and vascular disease. JAMA. 2003 Oct 8;290(14):1906-14. Review.</citation>
    <PMID>14532320</PMID>
  </reference>
  <reference>
    <citation>Hosogai N, Fukuhara A, Oshima K, Miyata Y, Tanaka S, Segawa K, Furukawa S, Tochino Y, Komuro R, Matsuda M, Shimomura I. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes. 2007 Apr;56(4):901-11.</citation>
    <PMID>17395738</PMID>
  </reference>
  <reference>
    <citation>Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet. 2005 Mar 19-25;365(9464):1046-53.</citation>
    <PMID>15781100</PMID>
  </reference>
  <reference>
    <citation>Coughlin SR, Mawdsley L, Mugarza JA, Wilding JP, Calverley PM. Cardiovascular and metabolic effects of CPAP in obese males with OSA. Eur Respir J. 2007 Apr;29(4):720-7. Epub 2007 Jan 24.</citation>
    <PMID>17251237</PMID>
  </reference>
  <reference>
    <citation>Lavie L. Obstructive sleep apnoea syndrome--an oxidative stress disorder. Sleep Med Rev. 2003 Feb;7(1):35-51. Review.</citation>
    <PMID>12586529</PMID>
  </reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2010</study_first_submitted>
  <study_first_submitted_qc>September 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2010</study_first_posted>
  <last_update_submitted>June 15, 2016</last_update_submitted>
  <last_update_submitted_qc>June 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adipose tissue</keyword>
  <keyword>obese patients</keyword>
  <keyword>inflammation</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>sleep apnea syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Panniculitis</mesh_term>
    <mesh_term>Steatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

